Department of Hematology

Introduction

Ten years have passed since I was appointed to this department in July 2007. Since then, we have been aiming to create a facility that can comprehensively treat all blood diseases, from hematological malignancies such as leukemia, malignant lymphoma and multiple myeloma, to anemia and other general hematological diseases. During the past decade, research on the molecular pathogenesis of blood diseases has progressed dramatically, and the development of new therapeutic drugs has progressed and introduced into the clinics. As a result, the improvement in the treatment outcomes for hematological malignancies over the last ten years has been remarkable. We have established a system that allows our facility to practice state-of-the-art medical care without being late in the flow. In addition to a medical treatment system where we can practical treatments from normal chemotherapy, to all kinds of hematopoietic stem cell transplantation and we have developed into one of the leading blood care facilities in Japan, which can also conduct early clinical trials with non-approved drugs. At the same time, we have been trying to develop a team medical system with multi-disciplinary roles, as well as patient-oriented medical care. There is consistency of activity with the establishment of seminars and public lectures that are easy for the patient advocacy group to understand.

In order to practice such advanced medicine, it is essential to improve the level of the individuals who contribute it within the entire organization, and it is necessary for them to obtain a medical degree along with the qualifications of a specialist of internal medicine and hematology. To achieve this, we strive to disseminate our research results not only domestically but also internationally without neglecting our daily efforts. The motto of our Department of Hematology is to "Learn about medical care, education and research with Vision, Passion, and Mission". We would like to accept young doctors who aim to learn hematology and as many patients as possible, and we strive to be a base for blood treatments centering on hematological malignancies.

The Department of Hematology at Saitama Medical Center,Saitama Medical University promotes the practice of medical treatment with a high degree of satisfaction for the patient, and we promote education with a wide international perspective for young physicians and students who are responsible for the next generation. We want to practice better blood treatment and endeavor to contribute to society through these kinds of daily activities.

Patient care at our department

Our hospital has total26 beds in cluding private rooms, as a sterilized ward, and is capable of treating all blood diseases, as well as hematological malignancies and general diseases. We are certified with the Japan Marrow Donor Program, thus we can perform all kinds of hematopoietic stem cell transplantation. It is one of the leading facilities in Saitama Prefecture as well as Japan, and we are actively conducting clinical trials. It is very important to provide medical care covering a wide range of diseases for for the treatment of blood diseases,therefore,we aim to provide high-quality medical care by accepting a wide range of emergency cases, including acute leukemia and other diseases, with flexibility.

As a basic policy for the therapeutic approaches, we select a treatment options on a scientific basis (Evidence Based Medicine) according to globally approved clinical data, we then explain the medical policy sufficiently to the patient and family, and obtain his or her agreement, and then we prioritize the medical care that they can receive with peace of mind.

In recent years, a variety of new drugs have been developed and applied in practice and are now being incorporated into the standard treatment for blood diseases. Our department actively uses new therapeutic drugs and immunotherapy which have been approved for insurance coverage. We are also contributing to the improvement of the treatment results for blood diseases by promoting clinical trials which we have led and through multi-facility joint testing at JCOG and JALSG and other trialgroups in Japan. In the same way, we are often selected as an implementation facility for clinical trials for new drugs that are not yet approved for medical treatment of blood diseases on a nationwide scale, and we conduct clinical trials for a number of new drugs. In this way, we are committed to providing a wide range of treatment options, ranging from normal standard treatments to clinical trials.

We are focusing not only on inpatient care but also on outpatient treatment. If patients are able to attend outpatient treatment and need chemotherapy with a blood transfusion or an anticancer agent, then that quality of life is preferred, and we actively choose to treat them as outpatients. We also cooperate with other departments in the hospital. Our hospital has one of the most comprehensive perinatal, maternal and child care centers in Japan, and we have experienced many cases of diagnosis and treatment of blood abnormalities associated with pregnancy. The most common cases of hematological malignancy are malignant lymphoma, but for the diagnosis of malignant lymphoma, Professor Junichi Tamaru, the Department of Pathology in our hospital, is one of the most prominent pathologist in Japan, and we regularly conduct conferences with the pathology department and aim for accurate diagnoses based on clinical and pathological information both.

Main diseases

• Acute leukemia (Acute myeloid leukemia, Acute lymphocytic leukemia, Adult T-cell leukemia)
• Chronic leukemia (Chronic myeloid leukemia, Chronic lymphocytic leukemia)
• Myelodysplastic syndromes
• Myeloproliferative neoplasms(Essential thrombocythemia, Poly polycythemia, Primary myelofibrosis)
• Malignant lymphoma (Hodgkin's lymphoma, non-Hodgkin's lymphoma, [Diffuse large B-cell lymphoma, Follicular lymphoma, Mantle cell lymphoma, MALT lymphoma, Burkitt lymphoma, Splenic marginal lymphoma, Adult T-cell lymphoma, peripheral T-cell lymphoma],etc)
• Multiple myeloma, macroglobulin, plasma cell carcinoma
• Anemia (Iron deficiency anemia, Megakoculblastic anemia, Hemolytic anemia, Paroxysmal nocturnal hemoglobinuria)
• Aplastic anemia, Pure red cell aplasia
• Blood clotting disorders (Hemophilia, Acquired hemophilia, Coagulation factor deficiency)
• Idiopathic thrombocytopenia purpura
• Thrombotic thrombocytopenic purpura
• Disseminated intravascular coagulation
• Thrombasthenia

Target Symptoms

• Issues found in health checkups, abnormalities in blood count, hypercytosis, cytopenia(leukocytosis/leukopenia/neutropenia/polycythemia/plethora/erythropenia/anemia/ thrombocytosis/thrombocytopenia/pancytopenia)
• Lymph node swelling
• Enlarged spleen
• Sustained fever, repeated fever, repeated infections, fever of unknown origin(fever that lasts more than three weeks after a hospital exam and for which the cause is unknown)
• Bleeding tendencies (abnormal bleeding, hemostatic difficulties, bruises, purpura, petechia)
• Anemia (malaise, weakness, shortness of breath, dizziness, etc.)

Treatment results

診療スタッフ

Name	Job Title	Position	Specialized Field	Credentials
多林　孝之 (TabayashiTakayuki)	Professor	Director of the department of Hematology Chief of Clinical Services Chief of Research	Multiple myeloma Malignant lymphoma Leukemia	Fellow of the Japanese Society of Internal Medicine(FJSIM) Board Certified Member of the Japanese Society of Hematology Board-certified Medical Oncologist of the Japanese Society of Clinical Oncology Board Certified Member of the Japanese Society for Transplantation and Cellular Therapy
髙橋　康之 (Takahashi Yasuyuki)	Instructor	Vice-Chief of Clinical Services Manager of Outpatient Services Chief of Education	Leukemia Malignant lymphoma Hematopoietic stem cell transplantation	Board Certified Member of the Japanese Society of Internal Medicine Board Certified Member of the Japanese Society of Hematology Board Certified Member of the Japanese Society for Transplantation and Cellular Therapy
永沼　謙 (Naganuma　Ken)	Instructor	Manager of Inpatient Sevices Vice-Chief of Education Vice-Chief of Research	Malignant lymphoma Hematopoietic stem cell transplantation Leukemia	Board Certified Doctor of Internal Medicine Board Certified Member of the Japanese Society of Hematology
坂田　憲幸 (Sakata Noriyuki)	Instructor		Leukemia Malignant lymphoma Multiple myeloma
川田　泰輔 (Kawada Taisuke)	Instructor		Malignant lymphoma Multiple myeloma Leukemia
松永　洸昂 (Matsunaga Takeaki)	Instructor		Malignant lymphoma Multiple myeloma Leukemia
齋藤　晟太郎 (Saito Seitaro)	Instructor		Malignant lymphoma Leukemia Multiple myeloma
荒井　祐太 (Arai Yuta)	Instructor		Leukemia Malignant lymphoma Multiple myeloma
木崎　昌弘 (Kizaki Masahiro)	Professor Emeritus		Leukemia Myelodysplastic syndromes Multiple myeloma	Fellow of the Japanese Society of Internal Medicine(FJSIM) Board Certified Member of the Japanese Society of Hematology
三ツ橋　雄之 (Mitsuhashi Takayuki)	Visiting Assistant Professor		Hematopathology Laboratory medicine	Councilor of the Japanese Society for Laboratory Hematology
平田 公美 (Hirata Kumi)	Visiting Instructor		Leukemia Malignant lymphoma Multiple myeloma
造血細胞移植コーディネーター HCTC (Hematopoietic cell Transplant coordinator)				Japanese Society for Transplantation and Cellular Therapy certification

Outpatient clinic

・初診は月曜日・水曜日・金曜日の受付です。
・初診外来はFAX診療予約申込（FAX診療予約サービス）による予約制となります。医療機関からの紹介申込みとなります。
・FAX診療予約につきましては、当冊子2ページまたは当院病診連携室のホームページをご参照ください。

To the Medical Institutions

We treat all blood diseases, from hematological malignancies including acute leukemia, chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, to aplastic anemia, idiopathic thrombocytopenia purpura disease, myelofibrosis, coagulation disorders, EB viral infections, and cytomegalovirus infections, and other non-neoplastic diseases. Please refer patients to our department if they are suspected of having a blood diseases such as an abnormality in their blood couns or specific symptoms, if they have been diagnosed with a hematological malignancy in a pathological tissue diagnosis, or if they are relocating close to our hospital for medical treatment of a blood diseases. If they have a medical history in another hospital, they should bring their doctor's information (referral letter). That makes it possible to perform the medical treatment smoothly, so they should bring as much as possible.

We accept first visits on Saturdays, but there are several limitation that cannot be examined of genetic and bone marrow examinations necessary for diagnosing blood diseases. If necessary, we may ask them to visit again on weekdays from Monday to Friday. The doctor will instruct them at the time of their consultation.

Our hospital is a transplant facility accredited by the Japan Marrow Donor Program. In addition to transplantation of hematopoietic stem cells from related and unrelated donors umbilical cord blood transplantation from the Japan Marrow Donor Program donors are also actively utilized, if adaptable.

We also conduct a number of clinical trials. If you have patients who are interested in a clinical trial for a target diseases, we would appreciate it if you could refer them to us. In this case, we would like to ask you to provide their medical information.

We also provide second opinions for outpatients. The second opinion is separate from the outside frame of medical insurance, so we will have enough time in the second opinion frame for the patients who want our second opinion. We would ask that you apply for a visit to the specific second opinion outpatient clinic instead of for the regular outpatient clinics.

In the case of an emergency, etc., we will respond whenever possible even when outside the initial admission time. Please contact us by phone (049-228-3569) at the outpatient clinic until 17:00 on weekdays and Saturdays. Nighttime and holiday correspondence is done via the duty doctor. Please call us at the nighttime and holiday telephone reception (049-228-3595) at our hospital.